Thus, understanding the underlying mechanisms is mandatory to provide future possible therapeutic concepts for delayed fracture healing and metabolic bone diseases, e.g. osteoporosis, especially, as the reported in vitro and in vivo experiments administered TGF-β only for short times, which precludes an evaluation of the skeletal actions of TGF-β at steady state. The gene discussed is TGFB1; the disease is osteoporosis.